T
Turn Therapeutics
Advanced wound care solutions reducing antibiotic resistance with innovative, clinically-backed products
About Turn Therapeutics
Turn Therapeutics is a pharmaceutical and medical device company focused on reducing the human and economic costs of infection and skin disease. The company operates in the healthcare market, specifically targeting acute and chronic wound care. Turn Therapeutics serves healthcare providers, hospitals, and clinics that require advanced wound care solutions. The business model revolves around the development and commercialization of innovative therapeutic candidates that are backed by clinical evidence and real-world feedback. Revenue is generated through the sale of these advanced wound care products and medical devices. The company's flagship technology, PermaFusion, is a liquid in oil suspension that enhances the effectiveness of topical treatments while minimizing risks such as toxicity and irritation. By using less active ingredient without compromising efficacy, Turn Therapeutics aims to reduce antibiotic resistance and improve patient outcomes. The company is committed to continuous innovation and education to make diseases obsolete.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2015
- Headquarters
- Thousand Oaks, United States
- Listing
- IPO 2025
- Employees
- 10
- Open positions
- None listed
- Dealroom signal
- 87.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO DEBTDebt | Mar 2026 | $7M | — | Avenue Capital Group | ↗ |
| IPOOther financing | Oct 2025 | $0 | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $0 | — | −$1.7M | — |
| 2025 | $0 | — | −$1.7M | — |
| 2024 | $0 | — | −$1.7M | — |
| 2023 | $0 | — | −$2.3M | — |
Growth signals
Latest recorded traffic for Turn Therapeutics is 7.5K monthly website visits, down 46.4% over the last three months. Turn Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
StartEngine
Series B and later2 investors entered at this stage
Global Emerging Markets
Avenue Capital Group
Other known investors1 additional known investor
Suriyaa Sundararuban
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Turn Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Turn Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.